Intrahepatic injection of recombinant adeno-associated virus serotype 2 overcomes gender-related differences in liver transduction

Human Gene Therapy

Volumn 17, Issue 6, 2006, Pages 601-610

  Berraondo, Pedro ^a,b   Crettaz, Julien ^a   Ochoa, Laura ^a   Pañeda, Astrid ^a   Prieto, Jesús ^a   Trocóniz, Iñaki F ^c   González Aseguinolaza, Gloria ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b INSTITUT PASTEUR   (France)

^c Faculty of Pharmacy   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DISTRIBUTION; GENETIC TRANSDUCTION; INTRAHEPATIC DRUG ADMINISTRATION; LIVER; MOUSE; NONHUMAN; PORTAL VEIN; PROTEIN EXPRESSION; SEX DIFFERENCE; SPLEEN; TISSUE DISTRIBUTION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ANIMALS; DEPENDOVIRUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; FEMALE; GENE THERAPY; HEPATIC ARTERY; INJECTIONS, INTRA-ARTERIAL; LIVER; LUMINESCENT AGENTS; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECOMBINANT PROTEINS; SEX FACTORS; TRANSDUCTION, GENETIC; TRANSGENES;

ADENO-ASSOCIATED VIRUS;

EID: 33745673347     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.601     Document Type: Article

References (33)

1. ALEXANDER, I.E., RUSSELL, D.W., and MILLER, A.D. (1994). DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J. Virol. 68, 8282-8287.
2. BARTLETT, J.S., WILCHER, R., and SAMULSKI, R.J. (2000). Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J. Virol. 74, 2777-2785.
3. BERRAONDO, P., OCHOA, L., CRETTAZ, J., ROTELLAR, F., VALES, A., MARTINEZ-ANSO, E., ZARATIEGUI, M., RUIZ, J., GONZÁLEZ-ASEGUINOLAZA, G., and PRIETO, J. (2005). IFN-α gene therapy for woodchuck hepatitis with adeno-associated virus: Differences in duration of gene expression and antiviral activity using intraportal or intramuscular routes. Mol. Ther. 12, 68-76.
4. BESSIS, N., GARCIACOZAR, F.J., and BOISSIER, M.C. (2004). Immune responses to gene therapy vectors: Influence on vector function and effector mechanisms. Gene Ther. 11, 10-17.
5. BUNING, H., BRAUN-FALCO, M., and HALLEK, M. (2004). Progress in the use of adeno-associated viral vectors for gene therapy. Cells Tissues Organs 177, 139-150.
6. CHEN, Z.Y., YANT, S.R., HE, C.Y., MEUSE, L., SHEN, S., and KAY, M.A. (2001). Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver. Mol. Ther. 3, 403-410.
7. DALY, T.M. (2004). AAV-mediated gene transfer to the liver. Methods Mol. Biol. 246, 195-199.
8. DAVIDOFF, A.M., NG, C.Y., ZHOU, J., SPENCE, Y., and NATHWANI, A.C. (2003). Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 102, 480-488.
9. DODGE, J.C., CLARKE, J., PASSINI, M.A., SONG, A., O'RIORDAN, C.R., CHENG, S.H., and STEWART, G.R. (2005). Sex and estrous cycle stage influence the efficiency of AAV-mediated gene transfer in the rodent brain. American Society of Gene Therapy, 8th Annual Meeting. Mol. Ther. 11, S192.
10. DUROCHER, Y., PERRET, S., and KAMEN, A. (2002). High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 30, E9.
11. FERRARI, F.K., SAMULSKI, T., SHENK, T., and SAMULSKI, R.J. (1996). Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70, 3227-3234.
12. HARDING, T.C., KOPRIVNIKAR, K.E., TU, G.H., ZAYEK, N., LEW, S., SUBRAMANIAN, A., SIVAKUMARAN, A., FREY, D., HO, K., VANROEY, M.J., NICHOLS, T.C., BELLINGER, D.A., YENDLURI, S., WAUGH, J., MCARTHUR, J., VERES, G., and DONAHUE, B.A. (2004). Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B. Gene Ther. 11, 204-213.
13. HIGH, K.A. (2002). AAV-mediated gene transfer for hemophilia. Genet. Med. 4, 56S-61S.
14. HIGH, K.A. (2004). Clinical gene transfer studies for hemophilia B. Semin. Thromb. Hemost. 30, 257-267.
15. LAI, C.M., LAI, Y.K., and RAKOCZY, P.E. (2002). Adenovirus and adeno-associated virus vectors. DNA Cell Biol. 21, 895-913.
16. LEBHERZ, C., GAO, G., LOUBOUTIN, J.P., MILLAR, J., RADER, D., and WILSON, J.M. (2004). Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J. Gene Med. 6, 663-672.
17. LUDDEN, T.M., BEAL, S.L., and SHEINER, L.B. (1994). Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J. Pharmacokinet. Biopharm. 22, 431-445.
18. MCCARTY, D.M., YOUNG, S.M., JR., and SAMULSKI, R.J. (2004). Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu. Rev. Genet. 38, 819-845.
19. MIAO, C.H., NAKAI, H., THOMPSON, A.R., STORM, T.A., CHIU, W., SNYDER, R.O., KAY, M.A. (2000). Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: Cell cycling does not influence hepatocyte transduction. J. Virol. 74, 3793-3803.
20. MITCHELL, M., JEREBTSOVA, M., BATSHAW, M.L., NEWMAN, K., and YE, X. (2000). Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors. Gene Ther. 7, 1986-1992.
21. MOCHIZUKI, S., MIZUKAMI, H., OGURA, T., KURE, S., ICHINOHE, A., KOJIMA, K., MATSUBARA, Y., KOBAYAHI, E., OKADA, T., HOSHIKA, A., OZAWA, K., and KUME, A. (2004). Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice. Gene Ther. 11, 1081-1086.
22. NAKAI, H., YANT, S.R., STORM, T.A., FUESS, S., MEUSE, L., and KAY, M.A. (2001). Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J. Virol. 75, 6969-6976.
23. NAKAI, H,. THOMAS, C.E., STORM, T.A., FUESS, S., POWELL, S., WRIGHT, J.F., and KAY, M.A. (2002). A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction. J. Virol. 76, 11343-11349.
24. NAKAI, H.T., STORM, T.A., and KAY, M.A. (2000). Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J. Virol. 74, 9451-9463.
25. OHASHI, K., NAKAI, H., COUTO, L.B., and KAY, M.A. (2005). Modified infusion procedures affect recombinant adeno-associated virus vector type 2 transduction in the liver. Hum. Gene Ther. 16, 299-306.
26. QING, K., KHUNTIRAT, B., MSH, C., KUBE, D.M, WANG, X.S., PONNAZHAGAN, S., ZHOU, S., DWARKI, V.J., YODER, M.C., and SRIVASTAVA, A. (1998). Adeno-associated virus type 2-mediated gene transfer: Correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo. J. Virol. 72, 1593-1599.
27. SANLIOGLU, A.D., KARACAY, B., BENSON, P.K., ENGELHARDT, J.F., and SANUOGLU, S. (2004). Novel approaches to augment adeno-associated virus type-2 endocytosis and transduction. Virus Res. 104, 51-59.
28. SNYDER, R.O., MIAO, C.H., PATIJN, G.A., SPRATT, S.K., DANOS, O., NAGY, D., GOWN, A.M., WINTHER, B., MEUSE, L., COHEN, L.K., THOMPSON, A.R., and KAY, M.A. (1997). Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet. 16, 270-276.
29. β5 integrin: A co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5, 78-82.
30. SUN, B., ZHANG, H., FRANCO, L.M., YOUNG, S.P., SCHNEIDER, A., BIRD, A., AMALFITANO, A., CHEN, V.T., and KOEBERL, D.D. (2005). Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol. Ther. 11, 57-65.
31. THOMAS, C.E., STORM, T.A., HUANG, Z., and KAY, M.A. (2004). Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J. Virol. 78, 3110-3122.
32. WANG, L., CALCEDO, R., NICHOLS, T.C., BELLINGER, D.A., DILLOW, A., VERMA, I.M., and WILSON, J.M. (2005). Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood 105, 3079-3086.
33. ZHONG, L., LI, W., YANG, Z., CHEN, L., LI, Y., QING, K., WEIGEL-KELLEY, K.A., YODER, M.C., SHOU, W., and SRIVASTAVA, A. (2004). Improved transduction of primary murine hepatocytes by recombinant adeno-associated virus 2 vectors in vivo. Gene Ther. 11, 1165-1169.